MedPath
Found 1 clinical trials|View Analysis
Sort by:

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Phase 1
Recruiting
Conditions
Ovarian Cancer
Recurrent Solid Tumor
Urinary Bladder Neoplasm
Esophageal Cancer
Renal Pelvis Cancer
Advanced Solid Tumor
Prostate Cancer
Metastatic Solid Tumor
Triple Negative Breast Cancer
Bladder Cancer
Interventions
Drug: LY4101174
First Posted Date
2024-02-02
Last Posted Date
2024-11-18
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
280
Registration Number
NCT06238479
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

Advent Health Orlando, Orlando, Florida, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 13 locations
© Copyright 2025. All Rights Reserved by MedPath